GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (STU:0M4) » Definitions » Total Equity

Mersana Therapeutics (STU:0M4) Total Equity : €0.95 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mersana Therapeutics Total Equity?

Mersana Therapeutics's total equity for the quarter that ended in Sep. 2024 was €0.95 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Mersana Therapeutics Total Equity Historical Data

The historical data trend for Mersana Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Total Equity Chart

Mersana Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only 70.49 187.49 107.74 86.90 33.84

Mersana Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.91 33.84 25.75 7.83 0.95

Mersana Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Mersana Therapeutics's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=207.297-173.456
=33.84

Mersana Therapeutics's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=152.747-151.801
=0.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mersana Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Mersana Therapeutics Business Description

Traded in Other Exchanges
Address
840 Memorial Drive, Cambridge, MA, USA, 02139
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics Headlines

No Headlines